Illuminating Lennox-Gastaut syndrome

rare-disease-large-blue

For National Epilepsy Awareness Month, Dr Nicola Davies shines a light on a rare form of epilepsy – Lennox-Gastaut syndrome (LGS).

What is LGS?

LGS is a severe and rare form of childhood-onset epilepsy, typically presenting in children aged 3-5 years. The condition is slightly more common in males than females and can persist into adulthood. While the long-term prognosis of the disease varies, complete seizure control and normal development is rare.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical